142 related articles for article (PubMed ID: 22044804)
1. Bone health in breast cancer survivors.
Abdel-Razeq H; Awidi A
J Cancer Res Ther; 2011; 7(3):256-63. PubMed ID: 22044804
[TBL] [Abstract][Full Text] [Related]
2. Denosumab and the current status of bone-modifying drugs in breast cancer.
Lee BL; Higgins MJ; Goss PE
Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
[TBL] [Abstract][Full Text] [Related]
3. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer.
Swenson KK; Henly SJ; Shapiro AC; Schroeder LM
Clin J Oncol Nurs; 2005 Apr; 9(2):177-84. PubMed ID: 15853161
[TBL] [Abstract][Full Text] [Related]
4. Low bone density in breast cancer survivors in Korea: prevalence, risk factors and associations with health-related quality of life.
Kim SH; Cho YU; Kim SJ; Lee JE; Kim JH
Eur J Oncol Nurs; 2013 Apr; 17(2):196-203. PubMed ID: 22898655
[TBL] [Abstract][Full Text] [Related]
5. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
7. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
8. Cancer treatment-induced bone loss.
Adler RA
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):442-5. PubMed ID: 17982349
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive therapies in oncology and their effects on cancer progression.
Bundred N
Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
[TBL] [Abstract][Full Text] [Related]
11. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
12. Bone health management of Australian breast cancer survivors receiving hormonal therapy.
Roberts R; Miller M; O'Callaghan M; Koczwara B
Intern Med J; 2015 Nov; 45(11):1182-5. PubMed ID: 26348867
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
Theriault RL
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of osteoporosis in women with a history of breast carcinoma.
Van Poznak C; Sauter NP
Cancer; 2005 Aug; 104(3):443-56. PubMed ID: 15968687
[TBL] [Abstract][Full Text] [Related]
15. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
Rosen LS
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH;
J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561
[TBL] [Abstract][Full Text] [Related]
17. Bone complications of androgen deprivation therapy: screening, prevention, and treatment.
Lattouf JB; Saad F
Curr Opin Urol; 2010 May; 20(3):247-52. PubMed ID: 20224416
[TBL] [Abstract][Full Text] [Related]
18. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Hershman D; Narayanan R
Curr Oncol Rep; 2004 Jul; 6(4):277-84. PubMed ID: 15161581
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
[TBL] [Abstract][Full Text] [Related]
20. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Gnant M
Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
